Helen Aspasia Petousis-Harris is a New Zealand vaccinologist and associate professor in the Department of General Practice and Primary Health Care at the University of Auckland. She has been involved in research related to vaccination in New Zealand since 1998, with her main areas of focus being vaccine safety and effectiveness. Petousis-Harris has had a variety of lead roles in New Zealand and international organisations that focus on vaccination and is a regular media spokesperson in this field, especially during the COVID-19 pandemic.
Career From 1999 to 2002 Petousis-Harris was a researcher at the University of Auckland, working with the Immunisation Advisory Centre, a New Zealand-wide organisation based at the university. She continued in various roles at the centre, including honorary assistant research fellow and director of research from 1998. Between 2008 and 2011, she worked on her doctorate and wrote a thesis titled Factors associated with vaccine reactogenicity in school aged children and young adults following administration of two protein-based vaccines. Petousis-Harris was a senior lecturer at the Department of General Practice and Primary Health Care, University of Auckland from 2012 until February 2020 when she attained the position of associate professor. In 2013 The Immunisation Advisory Centre (IMAC) set up the Vaccine Safety Expert Advisory Group, composed of "clinicians, scientists and policymakers who [had] either expertise and/or a professional interest in the safety of vaccines used in New Zealand", and Petousis-Harris has been a member of the group since it began. Petousis-Harris became group director in 2018 of the Vaccine Datalink and Research Group, which is based at Auckland University and has a primary goal of "investigating the risks and benefits of vaccines using pharmacoepidemiologic approaches...[and]...vaccine development, vaccine immunology, and vaccine risk communication". Working with Steven Black, a "specialist in paediatric infectious diseases and vaccinology who had led major projects for the American Centres for Disease Control (CDC) and for the World Health Organization", Petousis-Harris established the internationally networked Global Vaccine Data Network (GVDN) in 2019. As of 2023 she remains co-director of GVDN, a role held since the beginning of the project. Petousis-Harris was a member of the World Health Organization Global Advisory Committee on Vaccine Safety in 2017, being chair 2018–2020. and is a former member of the International Brighton Collaboration Science Board. As from 2020, Petousis-Harris has been a member of the COVID-19 Immunisation Implementation Advisory Group (IIAG) which provides advice for the New Zealand Ministry of Health to implement the COVID-19 immunisation campaign, and part of the COVID-19 Vaccine Technical Advisory Group (CV TAG).
Areas of expertise
Pneumococcal vaccines A paper by Petousis-Harris in 2013 traced the history of the development of capsular polysaccharide vaccines against S. pneumoniae and noted the importance of this programme in reducing community-acquired pneumonia (CAP), bacterial meningitis, bacteremia and otitis media (OM), commonly known as middle ear infection. The same paper signalled concerns about ethnic inequalities in New Zealand with regard to hospital admissions due to this, and Petousis-Harris cited research that showed: an increase in acute hospital admissions for infectious diseases in general between 1989 and 2008 and most significantly for LRI. Hospitalisation for pneumonia and influenza almost doubled during this time period and age-standardised hospitalisations for Māori and Pacific increased progressively throughout the 1990s Petousis-Harris concluded that while vaccination was important for Maori and Pacific Island children, these inequalities may also result from factors such as overcrowding, poor housing and access to primary health care. In 2015, research by Petousis-Harris and Colin Barber presented at the Annual Scientific Meeting of the Australasian Society for Infectious Diseases, showed preliminary figures that the rates of hospitalisation from invasive pneumococcal disease in children aged six years and under, had halved, with a 70% reduction for Maori and Pacific children. Prior to the conference, Petousis-Harris had drawn attention to the risks of children suffering permanent hearing loss if ear infections were not dealt with promptly by vaccination. In particular, along with her colleague, Colin Barber, she noted that compared to Pakeha children, almost twice as many Maori and Pacific Island children were at risk, with one-in-ten failing hearing tests when they started school. The study showed that vaccination helped reduce middle ear infections, and urged parents to monitor their children closely. Petousis-Harris earlier said the study demonstrated that the vaccine Synflorix reduced pneumonia, middle ear infections and hospitalisation from invasive pneumococcal disease (IPD).
… excerpt ends here. Continue reading the full article.
